Research into dangerous viruses and bacteria is important, but for the deadliest pathogens, it’s not clear the benefits are worth the risks.
Incidents causing potential exposures to pathogens occur frequently in the high security laboratories. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab.
Clinical laboratories, such as public health or academic labs, commonly conduct procedures involving pathogens that are infectious via inhalation.
There are only four companies in the world that have successfully commercialized Botox, but Korea has three: Medytox, Daewoong Pharmaceuticals and Hugel.
Fewer than one-in-10 countries have met global standards for securing high-consequence pathogens, increasing risks of an accidental disease outbreak or bioterrorism, a campaign group has warned. Just 19 countries completing a United Nations safety check have built or shown strong biosecurity safeguards.
By simulating the occurrence of a containment breach in their own countries, participants could critically review and update their respective national plans for responding to such an event in a poliovirus essential facility (PEF). They could also identify potential deficiencies in their countries’ overall emergency response and contingency planning systems.
The US Army made recommendations for improving safety and security at US Department of Defense (DOD) laboratories that handle Biological Select Agents and Toxins (BSAT). This report is the US Government Accountability Organization (GAO) review of DOD’s actions to address the Army’s recommendations.
More than three years have passed since news emerged that the Army inadvertently shipped 575 samples of live Bacillus anthracis to nearly 200 labs and contractors across the globe between 2004 and 2015.
To ensure the safety of those within and outside laboratory facilities, country-specific biosafety regulations are put in place by local authorities.
State and local health jurisdictions should consider regular communication with veterinary and laboratory communities regarding occupational RB51 exposures and can serve as a resource to clinicians unfamiliar with management of human Brucella abortus strain RB51 vaccine Brucella infections and exposures.